Geerts Farma SRL
Geerts Farma reported total assets of €1.38m at the end of the 2025 financial year (annual accounts filed with the NBB on 13 Aug 2026).
The score of Geerts Farma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +57 % Total assets +11 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Geerts Farma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 100,619 € | ||||
| Equity | 939,581 € | ||||
| Cash | 111,563 € | ||||
| EBITDA | 156,388 € | ||||
| Total assets | €1.38m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 13 Aug 2026
- Year ended 31 Dec 2024filed on 18 Jul 2025
- Year ended 31 Dec 2023filed on 20 Aug 2024
- Year ended 31 Dec 2022filed on 31 Jul 2023
- Year ended 31 Dec 2021filed on 19 Aug 2022
Geerts Farma's financial analysis
- Solvency68.3%sector median: 44.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Geerts Farma
Geerts Farma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0837.541.253
- VAT number
- BE0837541253
- Peppol
- Registered · 0208:0837541253 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 04 Jul 2011
- Registered office
- 1800 Vilvoorde
- Latest accounts
- 2025 · filed on 13 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Geerts Farma (SRL) has been based in Vilvoorde since 2011, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 100,619 € and equity of 939,581 €; its revenue is not published. Its solvency stands at 68.3%, above the median of its sector (44.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Geerts Farma
Companies in the same business, of comparable size and area, outside its group.
- De Spiegeleere - Discart Retail sale of pharmaceutical products Braine-l'Alleud · balance sheet €1.36m
- Decopharma Retail sale of pharmaceutical products Sint-Niklaas · balance sheet €1.36m
- Pharmacie de Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- EVDW Retail sale of pharmaceutical products Ghent · balance sheet €1.38m
- AD Pharma Retail sale of pharmaceutical products Châtelet · balance sheet €1.37m
- Apogrez Retail sale of pharmaceutical products Grez-Doiceau · balance sheet €1.37m
- Mast & Co Retail sale of pharmaceutical products Merchtem · balance sheet €1.36m
- Rafar Retail sale of pharmaceutical products Chimay · balance sheet €1.40m
Frequently asked questions about Geerts Farma
What is the revenue of Geerts Farma?
Geerts Farma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Geerts Farma?
In Belgium, the VAT number is the company number prefixed with BE: BE0837541253 for Geerts Farma, if the company is VAT-registered. Its company number (CBE) is 0837.541.253.
Where is the registered office of Geerts Farma?
According to the CBE register, the registered office of Geerts Farma is in 1800 Vilvoorde.
What is the equity of Geerts Farma?
At the close of the 2025 financial year, the equity of Geerts Farma amounts to 939,581 €, a solvency of 68.3% of total assets.
Who manages Geerts Farma?
The register lists 1 active mandates at Geerts Farma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Geerts Farma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →